Interview With EMA’s Eric Abadie
Posted 01 March 2011 | By
Dr. Eric Abadie is chairman of the European Medicines Agency (EMA) Committee on Medicinal Products for Human Use (CHMP). He also chairs the agency's Pharmacovigilance Working Party (PhWG) and serves as member of the Committee for Orphan Medicinal Products (COMP). Abadie has more than 25 years of experience in the pharmaceutical industry and is currently the scientific advisor to the director general of Agence française de sécurité sanitaire des produits de santé, France's national Competent Authority. In his roles with CHMP and PhWG, he is at the forefront of EMA's personalized medicine initiative. Regulatory Focus recently had the opportunity to talk with Abadie about the agency's viewpoint on this innovative approach to developing medicinal products.